Kornimate/medical-research-clean huggingface dataset:
physiotherapy treatment of shoulder rotator cuff tendinopathies. global postural reeducation or aerobic exercise?

Conditions: Rotator Cuff Tendinosis

Summary: the goal of this clinical trial is to compare in participant population (patients with rotator cuff tendinopathy of the shoulder) the effect of a global postural reeducation (gpr) program vs. a nonspecific therapeutic (aerobic) exercise program

participants who meet the inclusion criteria will be randomly distributed between group 1 "gpr", group 2 "exercise", or group 3 "no physical therapy intervention". group 1 participants will receive a physical therapy treatment using the gpr method for 6 weeks consisting of 1 weekly session lasting 40 min performing "frog on the ground" and "sitting" poses. patients in this group will also perform self-postures at home daily for 10 minutes. group 2 participants perform training for 6 weeks using non-specific aerobic exercise consisting of a daily 20-minute walk at a speed of 4-5 km/h. group 3 participants will not receive any physical therapy treatment and will serve as a control group.

Eligibility criteria:
inclusion criteria: * shoulder pain with duration of at least 3 months * positive painful arc test during abduction * at least one positive of the following tests: hawkins-kennedy test, neer's sig, empty can test, drop arm or lift-off test exclusion criteria: * cervical radiculopathy * moderate or severe degenerative arthropathy * complete rotator cuff tear * history of shoulder or neck surgery * history of shoulder fractures or dislocation * frozen shoulder or adhesive capsulitis * previous interventions with steroid injections or physiotherapy 2 months before the start of the program

Keywords: tendinopathy rotator cuff global postural reeducation aerobic exercice shoulder pain quality of life
evaluation of surgical risk in elderly patients submitted to elective surgery

Conditions: PERIPHERAL VASCULAR DISEASES; Digestive Diseases; BILIARY TRACT DISEASES

Summary: the purpose of this study is to establish the surgical risk factors and differences between different diseases in elderly patients submitted to elective surgery in our institution.


Eligibility criteria:
inclusion criteria: * patients older than 65 years of age * all necessary data to calculate p-possum and saps ii exclusion criteria: * patients with incomplete data

Keywords: surgical risk elderly major surgery p-possum saps ii
validity of a supersimplified device for diagnosis of patients with suspected obstructive sleep apnoea-hypopnoea (osah)

Conditions: Obstructive Sleep Apnea

Summary: the diagnosis of osash requires expensive sleep tests that generate long waiting lists, so we need simplified and rapid diagnostic tools. the apnealinktm, is a device that allows the assessment of respiratory events by measuring the flow ventilation with a nasal cannula connected to a pressure transducer.


Eligibility criteria:
inclusion criteria: 1. patients 18 to 75 years of both sexes. 2. clinical suspicion of osah defined as subjects with breathing pauses during sleep and / or asphyxiated sounds, with or without excessive daytime sleepiness as measured by the epworth scale and who have asked for a sleep test to rule out osah. 3. informed consent signed by the patient. exclusion criteria: 1. place of residence more than 100 km from the hospital. 2. inability to perform psychophysical study at home. 3. cardio-vascular disease, cerebro-vascular or respiratory or acute severe unstable as to preclude the proper conduct of studies at home and / or psg in the laboratory. 4. patients with chronic insomnia or recognize sleep less than six hours. 5. patients with depression (both point 4 and 5 are the potential causes of false negatives in a pr for lack of sufficient sleep time). 6. nasal obstruction complete or nearly complete, which prevents obtaining a quality signal with micromesam

Keywords: sleep apnoea diagnosis blood pressure body mass index breath analysis
retrospective evaluation of nivolumab in adjuvant esophageal cancer/gastroesophageal junction cancer

Conditions: Esophageal Cancer; Gastroesophageal Junction Cancer

Summary: the purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with stage ii/iii esophageal cancer/gastroesophageal junction cancer (ec/gejc) in china.


Eligibility criteria:
inclusion criteria: * participants aged 18 years or older at the index date * all patients must have stage ii or stage iii carcinoma of the esophagus or gastroesophageal junction and have histologically or cytologically confirmed predominant adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer at the time of initial diagnosis. * participants initiated nivolumab in adjuvant esophageal cancer (ec) or gastroesophageal junction cancer (gejc) treatment within the index window. exclusion criteria: * participation in a clinical trial of an investigational drug concurrently during the adjuvant nivolumab treatment. * from the date of diagnosis of ec or gjec to data end period, patients were diagnosed with a primary diagnosis of a cancer other than ec or gjec that requires systemic or other treatment

Keywords: esophageal cancer (ec) gastroesophageal junction cancer (gejc)
brief alcohol interventions with mobile phone applications for university students: a randomized controlled trial

Conditions: Problematic Alcohol Use

Summary: objectives: this study evaluates the efficacy of two mobile phone applications, promillekoll and partyplanner among university government members at two universities in stockholm, sweden. the design is a three-armed randomized controlled design, and outcomes are measured in terms of changes in problematic alcohol use at follow up 7 weeks after study initiation and baseline data gathering. both the promillekoll and partyplanner apps feature real time registration of alcohol consumption and giving feedback of estimated blood alcohol concentration levels. both apps inform and warn the user when the estimated alcohol level is above 0.6%, a level set that is below risky consumption levels. partyplanner additionally provides the possibility of simulating and planning an alcohol consumption event in advance and later on comparing it with the real time registration at the event. method: participants with problematic alcohol use (audit \>7 for men and \>5 for women) are randomized into one of three groups: 1. access to promillekoll, 2. access to partyplanner and 3. control group. outcomes on alcohol use as well as information on the users' satisfaction with the app assigned to them gathered after 7 weeks. the hypotheses are: 1. the groups receiving the promillekoll and partyplanner interventions will reduce their alcohol use to a larger extent than the control group at follow-up compared to the baseline level. 2. the addition of the possibility to plan events beforehand (partyplanner) will lead to an increased decrease in alcohol consumption to only real-time use (promillekoll).

background brief interventions via the internet have been shown to reduce university students' alcohol intake. this study tested two smartphone applications (apps) targeting drinking choices on party occasions, with the goal of reducing problematic alcohol intake among swedish university students. methods students were recruited via e-mails sent to student union members at two universities. those who gave informed consent, had a smartphone, and showed risky alcohol consumption according to the alcohol use disorders identification test (audit) were randomized into three groups. group 1 had access to the swedish government alcohol monopoly's app, promillekoll, offering real-time estimated blood alcohol concentration (ebac) calculation; group 2 had access to a web-based app, partyplanner, developed by the research group, offering real-time ebac calculation with planning and follow-up functions; and group 3 participants were controls. follow-up was conducted at 7 weeks.

Eligibility criteria:
inclusion criteria: * access to a smartphone running ios or android os. * audit \>7 for men or audit \>5 for women. exclusion criteria: * audit \<8 (men) or \<6 (women) * no access to a smartphone running ios or android os.

Keywords: randomized controlled trial alcohol internet mobile phone screening brief intervention
cpc in adult refractory glaucoma

Conditions: Refractory Glaucoma

Summary: the purpose of this study is to assess the relative effectiveness and safety of diode laser cyclophotocoagulation procedure to reduce iop and relieve pain in adult patients with refractory glaucoma.

a hospital -based, prospective interventional non comparative case series study.this study will be conducted on patients with refractory glaucoma whose ages are 18 years and older.they will be subjected to transscleral diode laser cyclophotocoagulation. postoperative evaluation will be scheduled for the first day postoperative, then 1 week later and then at 1st, 3rd, month postoperative.

Eligibility criteria:
inclusion criteria: * inclusion criteria: 1. patients with refractory glaucoma aging 18 years and older. 2. both sexes are included. 3. patients capable of giving informed consent. 4. pseudophkic glaucoma. 5. aphakic glaucoma. 6. silicon oil induced glaucoma. 7. neovascular glaucoma. 8. inflammatory glaucoma. exclusion criteria: 1. patients \<18 years of age. 2. patients controlled on regular antiglaucomatous therapy. 3. patients who cannot do regular follow up visits. 4. diffuse scleral staphyloma at the site of cpc.
idarubicin and high-dose cytarabine in treating patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more cancer cells. purpose: this phase ii trial is studying how well giving idarubicin together with high-dose cytarabine works in treating patients with acute myeloid leukemia.

objectives: * determine the complete remission rate (cr). * determine the proportion of patients who are bone marrow-positive at day 7 post-induction chemotherapy. * further evaluate the toxicity of this regimen. outline: patients receive cytarabine iv over 3 hours every 12 hours on days 1-4 and idarubicin iv over 5-10 minutes on days 1-3. patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. patients with \> 25% cellular biopsy or \> 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.

Eligibility criteria:
disease characteristics: inclusion criteria: * newly diagnosed acute myeloid leukemia (aml) * morphologic proof (bone marrow aspirate smears or touch prep of marrow biopsy) of disease * fab m0, m1, m2, m4, m5a, m5b, m6a, m6b, and m7 disease * previously untreated with radiotherapy or chemotherapy * patients with treatment-related leukemia are eligible even if they have received prior chemotherapy and radiotherapy * patients with prior myelodysplastic syndrome are eligible * extramedullary leukemia allowed * aml with lymphoid markers allowed exclusion criteria: * blastic transformation of chronic myelogenous leukemia * biphenotypic leukemia * fab m3 disease (acute promyelocytic leukemia) patient characteristics: * life expectancy ≥ 6 weeks * total bilirubin \< 1.5 g/dl * ast and alt \< 5 times upper limit of normal (uln) * creatinine \ 70 ml/min * ejection fraction ≥ 50% by muga unless decreased ejection fraction is secondary to leukemia infiltration * hiv antibody-negative prior concurrent therapy: inclusion criteria: * see disease characteristics * prior hydroxyurea or corticosteroids allowed * at least 48 hours since prior and no concurrent itraconazole or fluconazole exclusion criteria: * more than 300 mg/m² of prior daunorubicin or equivalent dose of anthracycline

Keywords: adult acute megakaryoblastic leukemia (m7) adult acute minimally differentiated myeloid leukemia (m0) adult acute monoblastic leukemia (m5a) adult acute monocytic leukemia (m5b) adult acute myeloblastic leukemia with maturation (m2) adult acute myeloblastic leukemia without maturation (m1) adult acute myelomonocytic leukemia (m4) adult erythroleukemia (m6a) adult pure erythroid leukemia (m6b) adult acute myeloid leukemia with 11q23 (mll) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) secondary acute myeloid leukemia untreated adult acute myeloid leukemia
phase ⅱ study of haic of folfox vs. sorafenib in hcc refractory to tace

Conditions: Hepatocellular Carcinoma

Summary: to evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (haic) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (hcc) refractory to transarterial chemoembolization(tace)

in most current guidelines, sorafenib is considered as the second-line treatment for patients with transarterial chemoembolization(tace) failure or refractoriness.however,the median overall survival of those treated with sorafenib monotherapy was 16.4 to 24.7 months. whether combining sorafenib with hepatic arterial infusion chemotherapy(haic) of oxaliplatin,5-fluorouracil and leucovorin is safe, well tolerated, and efficacious remains unknown, with no prospective clinical data currently available.the investigators therefore conducted a prospective and randomized phase ii trial to compare the safety and efficacy of haic with sorafenib in patients refractory to tace

Eligibility criteria:
inclusion criteria: * tace failure or refractoriness based on the liver cancer study group of japan (lcsgj) criteria, including appearance of vascular invasion or two or more consecutive insufficient responses of the intrahepatic lesion; * except for tace, patients have received no previous anti-tumor treatment; * the diagnosis of hcc was based on histological results; * patients must have at least one tumor lesion that can be accurately measured; * not amendable to surgical resection ,local ablative therapy and any other cured treatment; * no cirrhosis or cirrhotic status of child-pugh class a only; * no liver protection therapy in 2 weeks before enrolled, and meet the following laboratory parameters:(a) platelet count ≥ 75,000/μl; (b)hemoglobin ≥ 8.5 g/dl;(c) total bilirubin ≤ 30mmol/l;(d) serum albumin ≥ 32 g/l;(e) asl and ast ≤ 5 x upper limit of normal;(f) serum creatinine ≤ 1.5 x upper limit of normal;(g) inr \> 2.3 or pt/aptt within normal limits; (h) absolute neutrophil count (anc) \>1,500/mm3; * ability to understand the protocol and to agree to and sign a written informed consent document exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy; * known history of hiv; * history of organ allograft; * known or suspected allergy to the investigational agents or any agent given in association with this trial; * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy; * any other hemorrhage/bleeding event \> ctcae grade 3 within 4 weeks of first dose of study drug.

Keywords: hepatic arterial infusion chemotherapy sorafenib
dapsone gel 5% and tretinoin gel 0.025% versus tretinoin gel 0.025% monotherapy for facial acne vulgaris

Conditions: Acne Vulgaris

Summary: a 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tretinoin gel 0.025% compared with tretinoin gel 0.025% monotherapy in treating moderate to severe facial acne vulgaris


Eligibility criteria:
inclusion criteria: * facial acne vulgaris characterized by the following: * 30-100 facial inflammatory lesions; and, 25-100 facial non-inflammatory lesions; * stable disease, non-rapidly regressing facial acne vulgaris; and, less than or equal to 3 nodules and/or cysts (diameter greater than or equal to 1cm) * female subjects of childbearing potential must have a negative pregnancy test at baseline and practice reliable method of contraception throughout the study exclusion criteria: * non-compliance with washout period; * history of clinically significant anemia or hemolysis; * skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris; * allergy or sensitivity to any component of the test medications
a tolerance trial of cinobufacini injection intraperitoneal perfusion on digestive system cancer with ascites

Conditions: Digestive System Cancer; Malignant Ascites

Summary: to evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials. the clinical trial is divided into two parts, including single and successive administration.

to evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials. a single-arm, non-randomized, open, drug tolerance trial will be conducted. the clinical trial is divided into two parts, including single and successive administration.the single administration includes 7 groups, dose is escalated from 15ml to 180ml, with 2-6 patients per dose level. central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. this treatment will be given only once, and the volunteers will be observed for 24 hours. then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc. the successive administration includes 2 groups, according to the result of single administration, choose the second largest tolerance dose to conduct the 1st group of successive administration. if there are significant adverse effects, then drop to a lower dose to conduct the 2nd group; if the trial shows no adverse effects, it upgrades to a higher dose (the maximum tolerated dose) to conduct the 2nd group. the treatment will be given 3 times a week, 2 weeks as a period. adverse effects will be evaluated during and after treatment.

Eligibility criteria:
inclusion criteria: 1. digestive system cancer with malignant ascites; 2. the age of 18-80 years; 3. neither systemic chemotherapy, nor peritoneal perfusion therapy in 2 weeks; 4. no cinobufotalin preparations in 2 weeks; 5. ecog score 0-3; 6. the amount of ascites is above level ii (1000-3000ml); 7. volunteer to participate and sign informed consent. exclusion criteria: 1. non-cancer causes of ascites, such as peritonitis, cirrhosis，hypoalbuminemia; 2. had an allergy history to toad's skin or its products or had adverse reactions like arrhythmia when applied before; 3. b ultrasound or ct confirmed the peritoneal cavity is separated which will affect the treatment of ascites and the estimation of ascites; 4. the conditions admit and the patients would better to undergo chemotherapy of malignant ascites; 5. cardiac function is ⅲ-ⅳ; 6. alt\> 3 times upper limit and / or tbil\> 2 times upper limit; 7. renal function is phase 3 and above 3; 8. have severe neutropenia of degree ii or above, and / or moderate or severe anemia, and / or thrombocytopenia of degree ii or above; 9. consolidated mental disorders.
pilot study to evaluate the safety and efficacy of abatacept in adults and children 6 years and older with excessive loss of protein in the urine due to either focal segmental glomerulosclerosis (fsgs) or minimal change disease (mcd)

Conditions: Nephrotic Syndrome; Focal Segmental Glomerulosclerosis; Minimal Change Disease

Summary: the purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (fsgs) or minimal change disease (mcd). candidates must have a prior kidney biopsy with either diagnosis. another kidney biopsy will not be required as part of the study. candidates must have failed or be intolerant of prior therapy for their kidney disease. the failed or intolerant therapy must include corticosteroids and at least one other drug. candidates can be adults and children over the age of 6. abatacept will be administered by venous infusion every 4 weeks.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * male and female subjects ages ≥ 6 years * subjects resistant to corticosteroids, calcineurin inhibitors (cyclosporine and tacrolimus), sirolimus, mycophenolate mofetil (mmf), mycophenolic acid (mpa), or cyclophosphamide or intolerant to at least 2 of these * upcr ≥ 3 at screening * fsgs or mcd confirmed by renal biopsy * egfr ≥ 45 for children and adults * concomitant use of angiotensin-converting-enzyme inhibitor (acei) or angiotensin receptor blocker (arb) at stable doses for at least 2 weeks or have intolerance documented in the source documents maintained at the site exclusion criteria: * kidney diseases other than fsgs or mcd * collapsing fsgs * systemic lupus erythematosus * diabetes mellitus, both type 1 and type 2 * clinically significant congestive heart failure * post renal transplantation, including relapsing post-transplant fsgs * body mass index (bmi): \> 40 in subjects ≥ 18 years of age and ≥ 99% percentile for subjects \< 18 years of age other protocol defined inclusion/exclusion criteria may apply
once-daily investigational nasal spray in adults and adolescents with perennial allergic rhinitis (par)

Conditions: Rhinitis, Allergic, Perennial

Summary: the primary objective of this study is to compare the efficacy and safety of gw685698x 100mcg once daily (qd) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (par).

a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of gw685698x aqueous nasal spray 100mcg for 6 weeks in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (par)

Eligibility criteria:
inclusion criteria: * diagnosis of perennial allergic rhinitis (par). * must comply with study procedures and be literate. exclusion criteria: * significant concomitant medical conditions. * use of corticosteroids. * use of allergy and other identified medications during the study. * current tobacco use or tobacco use within the past year. * exposure to an investigational study drug within the past 12 months. * clinically significant abnormal electrocardiograms (ecg) or laboratory abnormality.

Keywords: gw685698x perennial allergic rhinitis allergic rhinitis